Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:1055-1064
Published online before print February 11, 2008, doi: 10.1161/CIRCULATIONAHA.107.749234
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
117/8/1055    most recent
CIRCULATIONAHA.107.749234v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Salio, M.
Right arrow Articles by Mantovani, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salio, M.
Right arrow Articles by Mantovani, A.
Related Collections
Right arrow Acute myocardial infarction
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrowRelated Article

(Circulation. 2008;117:1055-1064.)
© 2008 American Heart Association, Inc.


Molecular Cardiology

Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction

Monica Salio, PharmD; Stefano Chimenti, PharmD; Noeleen De Angelis, BiolD; Fabiola Molla, BiolD; Virginia Maina, BiolD; Manuela Nebuloni, MD; Fabio Pasqualini, BS; Roberto Latini, MD; Cecilia Garlanda, VetScD; Alberto Mantovani, MD

From the Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy (M.S., S.C., N.D.A., F.M., R.L.); Istituto Clinico Humanitas, IRCCS, Rozzano, Italy (V.M., F.P., C.G., A.M.); Pathology Unit, "L. Sacco" Department of Clinical Sciences (M.N.) and Institute of General Pathology (A.M.), University of Milan, Milan, Italy; and Department of Medicine, New York Medical College, Valhalla (R.L.).

Correspondence to Alberto Mantovani, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Italy. E-mail alberto.mantovani{at}humanitas.it

Received October 30, 2008; accepted December 14, 2008.

Background— Despite widespread clinical use as a prognostic marker in ischemic heart disorders, the actual pathogenetic role of the short pentraxin, C-reactive protein, has not undergone stringent genetic testing because of evolutionary divergence between mouse and humans. The long pentraxin PTX3 is conserved in evolution, is expressed in the heart under inflammatory conditions, and is a candidate prognostic marker in acute myocardial infarction. It was therefore important to assess whether PTX3 plays a pathogenetic role in acute myocardial infarction.

Methods and Results— In a model of acute myocardial infarction caused by coronary artery ligation and reperfusion, tissue mRNA expression and circulating levels of PTX3 increased. The interleukin-1R–MyD88 pathway plays a pivotal role in the induction of PTX3 transcript after ischemia. ptx3-deficient mice showed exacerbated heart damage (33% larger infarcts in null mice; P=0.0047). Increased myocardial damage in ptx3-deficient mice was associated with a greater no-reflow area, increased neutrophil infiltration, decreased number of capillaries, and increased number of apoptotic cardiomyocytes. In addition, ptx3-deficient mice with acute myocardial infarction showed higher circulating levels of interleukin-6 and increased C3 deposition in lesional tissue. The phenotype was reversed by exogenous PTX3.

Conclusions— Thus, PTX3 plays a nonredundant, regulatory, cardioprotective role in acute myocardial infarction in mice. Our results suggest that modulation of the complement cascade contributes to the cardioprotective function of PTX3.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 987-989. [Full Text]